Insilico Medicine's generative AI platform was credited in a press release with 'discovering' a promising pulmonary-fibrosis drug, but the company's patent named five human inventors, including CEO Alex Zhavoronkov, and did not mention AI.
Notes on verification
Directly confirmed by the original MIT Technology Review reporting and corroborated by multiple independent secondary sources summarizing the same facts; patent details also independently verifiable. [tier=unverified indep_score=0.3 clusters=4 claim_tier=notable] [rescored 2026-09-15: curated origin-host map (PR #65); unclassified hosts no longer scored as aggregators]
Sources
- MIT Technology Review (seed:technology_and_ai)
- https://www.artiverse.ca/the-five-human-names-behind-an-ai-designed-drug/ (corroboration)
- https://www.rajashreerajadhyax.com/post/when-ai-discovers-the-molecule-who-owns-the-invention (corroboration)
- https://bioethics.com/archives/103865 (corroboration)
- https://www.businessstory.org/2026/08/21/when-ai-designs-a-drug-who-gets-the-credit/ (corroboration)